<article>
<text>
<SENT sid="0" pm="."><plain>doi  10.1371/journal.pmed.1000156 </plain></SENT>
<SENT sid="1" pm="."><plain>snps doi sprot omim MIM </plain></SENT>
<SENT sid="2" pm="."><plain>Thereafter 100 ng of digested DNA was used to a PCR amplification of two fragments (F1 and F2) spanning part of the <italic>IRF-4</italic> promoter (<xref ref-type="bibr" rid="b30">30</xref>) (GenBank <ext-link ext-link-type="gen" xlink:href="U52683">U52683.1</ext-link>; see <xref ref-type="fig" rid="fig3">Figure 3A</xref>) </plain></SENT>
<SENT sid="3" pm="."><plain>SiteFind identified a potential <italic>BglII </italic>sequence overlapping with our desired R390S mutation of the KLF4 wild-type sequence [GenBank: <ext-link ext-link-type="gen" xlink:href="BC010301">BC010301</ext-link>] </plain></SENT>
<SENT sid="4" pm="."><plain>mim Modified from SwissProt, ID: <ext-link ext-link-type="sprot" xlink:href="P34056">P34056</ext-link> [68] </plain></SENT>
</text>
</article>
<article>
<text>
<SENT sid="5" pm="."><plain> omim 603878 </plain></SENT>
<SENT sid="6" pm="."><plain>3) Sequences specifically obtained for this study have been deposited in [accession: EF151088–EF151123 and EF998999].</plain></SENT>
<SENT sid="7" pm="."><plain>doi/10.1073/pnas.040460297 10.2210/PDB2OBS/PDB) </plain></SENT>
<SENT sid="8" pm="."><plain>doi doi:10.1594/PANGAEA.64577788) hi</plain></SENT>
<SENT sid="9" pm="."><plain>doi:10.15944/WDCC/HOAPS3_MONTHLY </plain></SENT>
<SENT sid="10" pm="."><plain><ext-link ext-link-type="doi" xlink:href="doi:10.1594/PANGAEA.64577">(10.1594/PANGAEA.64577)</ext-link> </plain></SENT>
<SENT sid="11" pm="."><plain>doi:10.1023/B:BEGE.0000023647.70223.1d </plain></SENT>
<SENT sid="12" pm="."><plain>Using the dominant mode, only one out of three of the X-linked SNPs, rs5916727, was </plain></SENT>
<SENT sid="13" pm="."><plain>Protein Data Bank (Accession codes 4FIQ and 4FIR for apo and R5P complex forms, respectively).</plain></SENT>
<SENT sid="15" pm="."><plain>The structure of Aedesin has been deposited at the Protein Data Bank (www.rcsb.org), under the entry assigned accession code: 2MMM.</plain></SENT>
<SENT sid="16" pm="."><plain>E-TABM-63</plain></SENT>
<SENT sid="17" pm="."><plain>ensembl ENSG00000149311</plain></SENT>
<SENT sid="18" pm="."><plain>pfam PF04083</plain></SENT>
<SENT sid="19" pm="."><plain>interpro  IPR000100</plain></SENT>
<SENT sid="20" pm="."><plain>go GO:0006915</plain></SENT>
<SENT sid="21" pm="."><plain>EGAD00000000001</plain></SENT>
<SENT sid="22" pm="."><plain>PXD000500</plain></SENT>
<SENT sid="23" pm="."><plain>SAME466412</plain></SENT>
<SENT sid="24" pm="."><plain>PRJDB3</plain></SENT>
<SENT sid="25" pm="."><plain>trial number: 2008-006074-15 and 2008-000430-45 in PMC4281162</plain></SENT>
<SENT sid="26" pm="."><plain>EGAS00000000087</plain></SENT>
<SENT sid="27" pm="."><plain>EMD-5778</plain></SENT>
<SENT sid="29" pm="."><plain>ClinicalTrials.gov NCT00888537, NCT01077037, NCT01029288, NCT00388050, NCT00578981, NCT00949611, NCT00217061</plain></SENT>
<SENT sid="30" pm="."><plain>TF330114</plain></SENT>
<SENT sid="31" pm="."><plain>SEQ ID NO: 4 (BPI; unnamed protein product [Homo sapiens] GenBank: BAG37729.1)</plain></SENT>
<SENT sid="32" pm="."><plain>GO:0006915</plain></SENT>
<SENT sid="33" pm="."><plain>pfam PF00389</plain></SENT>
<SENT sid="34" pm="."><plain>603878</plain></SENT>
<SENT sid="35" pm="."><plain>pdb 4day</plain></SENT>
<SENT sid="81996" pm="."><plain>The term "Bcl-2" as used herein refers to the
Bcl-2 protein(Swiss Prot ID No </plain></SENT>
<SENT sid="81997" pm="."><plain>P10415), a member of the Bcl-2 family of
proteins.The term "anti-Bcl-2 active agent" comprises "anti-Bcl-2 antisense
nucleotides" and Bcl-2 inhibitors" </plain></SENT>
<SENT sid="134" pm="."><plain>(Swiss Prot P04062, protein ID AAA35873),</plain></SENT>
<SENT sid="137" pm="."><plain>agents FR123392</plain></SENT>
</text>
</article>
